MXC: $0.023
We research

MGC has an ambitious international research and development agenda, supported by our scientific board and global relationships with high profile research institutions. MGC’s research and development projects include preclinical, clinical, botanical development and novel drug delivery systems, focused at the intersection of plant-derived medicines and the pharmaceutical industry.

The Company’s Clinical Advisory Team is responsible for leading the company’s development in three main areas of focus: Neurology, Oncology and Autoimmune.

Currently MGC’s research and development efforts and clinical trials are centered in Slovenia, Australia, Israel and India.



Royal Melbourne Institute of Technology (“RMIT”)

MGC has entered into an exclusive research agreement with RMIT, one of Australia’s leading universities. Pursuant to the agreement, the Company and RMIT have co-funded the construction of a state of the art research facility, where several avenues of research are currently being pursued, including:

Cancer research
Development of drug delivery systems for cannabinoid based products for cancer using nanotechnology targeting the CB2 receptors to control angiogenesis and inflammation.

Nanotechnology based drug delivery
Harnessing the nanotechnology based drug deliver experience of RMIT and The Hebrew University to develop delivery of cannabinoid formulations.

Combination of traditional medicine and cannabinoid therapies
Leverage to knowledge of traditional medicine and its research at RMIT to create new therapeutics by combing multiple compounds and exploring how they work together.

National Institute of Biology, Slovenia
MGC, in conjunction with NIB, has recently published data following successful preclinical research assessing the efficacy of phytocannabinoid-derived medicines on glioblastoma. This study is a long term, in vitro study with significant potential to create treatments for a currently untreatable indication.

Ongoing breeding project between the Biotechnical Faculty of the University of Ljubljana and MGC Pharmaceuticals.

MGC Pharmaceuticals genotypes were grown, flowered and harvested in the Faculties facilities and are undergoing EU registration:
MX-THC-10/3 37.83 THC 0.06 CBD
MXC-THC-81/5 0.70 THC 21.24 CBD
MXC-THC-40/3 29.46 THC 0.12 CBD
MXC-THC-40/2 14.56 THC 14.25 CBD

 

Developed for MGC by Graft Polymer DOO as part of the research agreement

CannEpil® – designed for treatment of Refractory Epilepsy
  • Phase IIb Clinical Trial at Schneider Hospital in Israel on the safety and efficacy of CannEpil® as an add on treatment in children and adolescents with refractory epilepsy
  • Controlled trial with Swinburne University of Technology, Melbourne to assess the effect of CannEpil® on driving performance
CogniCann® - designed for treatment of Dementia and Alzheimer’s disease
  • Phase II Clinical Trial with the University of Notre Dame in Perth, WA to evaluate the potential behavioural benefits CogniCann®may have on patients with dementia and Alzheimer’s disease
ArtemiC – designed for treatment of COVID-19
  • Phase II Clinical Trial on ArtemiC is designed to target viral infections with inflammatory complications, and currently the safety and efficacy is being evaluated on COVID-19 infected patients.  Trials are currently being undertaken at Nazareth Hospital EMMS and Hillel Yaffe Hospital in Israel, and Mahatma Gandhi Mission’s Medical College & Hospital, India